REHOVOT, Israel, Sept. 14, 2020 /PRNewswire/ --
CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that it has signed an agreement for distribution of its VergenixFlowable Gel (FG) product in six Commonwealth of Independent States (CIS) countries: Belarus, Kazakhstan, Georgia, Azerbaijan, Armenia and Uzbekistan.
The Company also reported that it has received the first order in an amount ofhundreds of thousands of U.S. dollars. Based on deal terms, CollPlant will deliver a portion of the order immediately and the remainder over the next six months. The distributor is a Swiss-headquartered pharmaceutical group of companies and the agreement is for a five-year period.
"This distribution agreement will enable new patient populations in the CIS to benefit from Vergenix FG use, which has also already elicited positive feedback in Europe for rapid recovery of chronic wounds," said Yehiel Tal, CEO of CollPlant. "We are proud of the transformative potential of our recombinant human collagen platform technology that facilitates optimal treatment options for patients and remain open to additional collaborations that will bolster commercial infrastructure for Vergenix FG as well as support for our pipeline development efforts. At the same time, we continue to strategically focus on innovative applications of our rhCollagen in medical aesthetics and 3D Bioprinting of organs and tissues. "
Vergenix FG is based on the Company's rhCollagen technology and is a wound-care product designed to treat acute and chronic hard-to-heal wounds, such as diabetic ulcers, pressure sores, surgical cuts and trauma wounds. A single applicationof the product provides an optimized treatment for the healing process until full wound closure.
Recently, a study was publishedin The Diabetic Foot Journal, Vol 23 No 2 2020, byIacopi E et al from the University Hospital in Pisa,Italy. The study demonstrated thatVergenixFG had excellent clinical outcomes inpatientswith post-surgicaldiabetic footwounds. VergenixFG has received CE marking and other regulatory approvals that allow sales and treatments in Europe, Israel and other countries.
About CollPlant
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.
Our products address indications for the diverse fields of tissue repair, aesthetics and organ manufacturing, and, we believe, are ushering in a new era in regenerative and aesthetic medicine.
Our flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. In October 2018, we entered into a licensing agreement with United Therapeutics, whereby United Therapeutics is using CollPlant's BioInks in the manufacture of 3D bioprinted lungs for transplant in humans.
In January 2020, we also entered into a Joint Development Agreement with 3D Systems Corporation, or 3D Systems, pursuant to which we and 3D Systems jointly develop tissue and scaffold bioprinting processes for third party collaborators. Our industry collaboration also includes the Advanced Regenerative Manufacturing Institute, or ARMI.
For more information about CollPlant, visithttp://www.collplant.com
Safe Harbor Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements.Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the outbreak of coronavirus; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk and products for medical aesthetics; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk and medical aesthetics products including but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact atCollPlant:
Eran RotemDeputy CEO & CFOTel: + 972-73-2325600Email: [emailprotected]
Sophia Ononye-Onyia, PhD MPH MBAFounder & CEO, The Sophia Consulting FirmTel: +1-347-851-8674E-mail: [emailprotected]|
SOURCE CollPlant
Read the rest here:
CollPlant Biotechnologies Signs Distribution Agreement for its Vergenix Flowable Gel Product in the Commonwealth of Independent States (CIS) -...
- Genetic Engineering and Its Applications StudyBullet.com - March 9th, 2025
- The Future of Gene-Editing Treatments for Rare Diseases - March 9th, 2025
- Biotechnology & Genetic Engineering: An Overview - Sciencing - March 9th, 2025
- Hoping to revive mammoths, scientists create 'woolly mice' - NPR - March 9th, 2025
- CRISPR Breakthrough Unlocks the Genetic Blueprint for ... - SciTechDaily - March 9th, 2025
- Mice have been genetically engineered to look like mammoths - The Economist - March 9th, 2025
- Gene modification can create bigger, better tomatoes, but should we do it? - Earth.com - March 9th, 2025
- "Colossal woolly mouse" created by scientists in effort to reconstruct the woolly mammoth - CBS News - March 9th, 2025
- Biotech company hoping to revive woolly mammoth, creates woolly mouse: Study - Straight Arrow News - March 9th, 2025
- Colossal Creates the Colossal Woolly Mouse, Showcasing Breakthroughs in Multiplex Genome Editing and Trait Engineering on the Path to a Mammoth -... - March 9th, 2025
- Colossal Biosciences is one step further in quest to bring back the woolly mammoth - Austin American-Statesman - March 9th, 2025
- Biotech Company Creates 'Woolly Mouse' as a Step in Its Quest to Resurrect Woolly Mammoths Through Gene Editing - Smithsonian Magazine - March 9th, 2025
- 'We didn't know they were going to be this cute': Scientists unveil genetically engineered 'woolly mice' - Livescience.com - March 9th, 2025
- These Genetically Engineered Mice Have Thick Woolly Mammoth Hair - ExtremeTech - March 9th, 2025
- Genetically altered mouse to pave way for resurrection of wolly mammoth? - Hindustan Times - March 9th, 2025
- Turning back the aging clock: Billions of dollars are probably being wasted on genetic manipulation techniques that likely wont work - Genetic... - March 9th, 2025
- OF WOOLLY MICE AND MAMMOTHS - Particle - March 9th, 2025
- Woolly mouse unveiled by firm hoping to bring more extinct animals back to life - The National - March 9th, 2025
- How scientists created woolly mice as part of their quest to bring back the woolly mammoth - The Indian Express - March 9th, 2025
- A Woolly What? - Brownstone Research - March 9th, 2025
- $1 Million Awarded to Continue to Develop Genetically Engineered Stem Cell Products to Fight Gastroesophageal Cancer - PR Newswire - February 15th, 2025
- Engineered animals show new way to fight mercury pollution - EurekAlert - February 15th, 2025
- Genetically modified foods: benefits and applications - Meer - February 15th, 2025
- Genetically modified zebrafish and fruit flies munch on mercury to make it less toxic - Yahoo - February 15th, 2025
- Principles of Genetic Engineering - PubMed Central (PMC) - February 7th, 2025
- The next 'big thing' in genetically modified crops: Drought-tolerant and herbicide resistant wheat. Here's what you need to know - Genetic Literacy... - February 7th, 2025
- Genetic engineering and biotechnology: The future of food is here - Yourweather.co.uk - February 7th, 2025
- Scientists Just Achieved a Major Milestone in Creating Synthetic Life - Yahoo! Voices - February 7th, 2025
- Two males give birth to child in incredible science experiment; the baby is now an adult | Mint - Mint - February 7th, 2025
- Genetic Engineering - The Definitive Guide | Biology Dictionary - January 27th, 2025
- Constitutive expression of Cas9 and rapamycin-inducible Cre recombinase facilitates conditional genome editing in Plasmodium berghei - Nature.com - January 27th, 2025
- What is Genetic Engineering? - Baker Institute - January 27th, 2025
- ARCUS breakthrough: An advanced gene editing tool appears to have cured an infant of an early onset metabolic disorder - Genetic Literacy Project - January 27th, 2025
- Your cells are dying. All the time. - Genetic Literacy Project - January 27th, 2025
- How Genetic Modification is Changing the Future of Conservation - MSN - January 27th, 2025
- Researchers genetically engineer yeast to produce healthy fatty acid - University of Alberta - January 27th, 2025
- genetic engineering summary | Britannica - September 13th, 2024
- The great gene editing debate: can it be safe and ethical? - BBC.com - September 13th, 2024
- Anti-biotechnology campaigners embrace classic crops, are suspicious of hybrid varieties and claim genetic modification violates nature. Heres a... - September 13th, 2024
- Will IL-11 Control Extend Human Life One Day? Early Results are Tantalizing - Securities.io - September 13th, 2024
- Viewpoint: As New Zealand edges toward relaxing its ban on gene edited foods, experts weigh in - Genetic Literacy Project - September 13th, 2024
- Farmers in Brazil and Argentina ramp up growing of genetically-modified drought tolerant wheat that can grow in subtropical regions - Genetic Literacy... - September 13th, 2024
- Scientist explains why we'll never have a real Jurassic Park - and people are crestfallen - indy100 - September 13th, 2024
- Genetic engineering techniques - Wikipedia - January 9th, 2024
- 20.3: Genetic Engineering - Biology LibreTexts - January 9th, 2024
- Genetic engineering - DNA Modification, Cloning, Gene Splicing - December 13th, 2023
- Global Gene Editing Market Poised for Significant Growth, Projected to Reach $14.28 Billion by 2027 - EIN News - December 13th, 2023
- Principles of Genetic Engineering - PMC - National Center for ... - May 17th, 2023
- Quitting: A Life Strategy: The Myth of Perseveranceand How the New Science of Giving Up Can Set You Free - Next Big Idea Club Magazine - May 17th, 2023
- 18 Human Genetic Engineering - Clemson University - March 29th, 2023
- Pros and Cons of Genetic Engineering - Benefits and Risks - March 29th, 2023
- How artificial skin is made and its uses, from treating burns to skin cancer - South China Morning Post - March 29th, 2023
- Genetic Engineering - Meaning, Applications, Advantages and Challenges ... - March 13th, 2023
- Revolutionary Specialty Enzymes Transform Industries, Projected to Reach $2.2 Billion by 2031 - Billion-Dollar - EIN News - March 5th, 2023
- Explained: What is genome editing technology and how is it different from GM technology? - The Indian Express - April 2nd, 2022
- Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference - Yahoo... - April 2nd, 2022
- San Antonio Zoo In Discussions on Woolly Mammoth Project - iHeart - April 2nd, 2022
- Xenotransplantation trials will require adjusting expectations, experts say - STAT - April 2nd, 2022
- 5 Interesting Startup Deals You May Have Missed In March: Restoring The Woolly Mammoth, Faux Seafood And Lots Of Bees - Crunchbase News - April 2nd, 2022
- Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for ... - KULR-TV - April 2nd, 2022
- The Bay Area food tech industry is creating more than vegan burgers. Heres whats next - San Francisco Chronicle - April 2nd, 2022
- Student Startup Teams to Compete For $110000 Cash Prize Pool in U of A's Heartland Challenge - University of Arkansas Newswire - April 2nd, 2022
- Should we test for differences in allergen content between varieties of crops and animal species? - Open Access Government - April 2nd, 2022
- Genetic Engineering - Courses, Subjects, Eligibility ... - December 22nd, 2021
- Scientists Used CRISPR Gene Editing to Choose the Sex of Mouse Pups - Singularity Hub - December 22nd, 2021
- Report calls for broad public deliberation on releasing gene-edited species in the wild - EurekAlert - December 22nd, 2021
- RNA and DNA Extraction Kit Market Study | Know the Post-Pandemic Scenario of the Industry - BioSpace - December 22nd, 2021
- Opinion: Allow Golden Rice to save lives - pnas.org - December 22nd, 2021
- It's time for an alliance of democracies | TheHill - The Hill - December 22nd, 2021
- Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19... - December 22nd, 2021
- 2021: when the link between the climate and biodiversity crises became clear - The Guardian - December 22nd, 2021
- Wuhan lab leak now the most likely cause of Covid pandemic and the truth WILL come out, experts tell MPs... - The US Sun - December 22nd, 2021
- Biotech ETFs That Outperformed Last Week - Yahoo Finance - December 22nd, 2021
- Human genetic enhancement - Wikipedia - October 5th, 2021
- Viewpoint: Part 1 Opposition stirred by anti-GMO advocacy group propaganda fading in the developing world, as more countries embrace crop... - October 5th, 2021
- Amyris Partners with Inscripta to Enhance Development of Sustainable Ingredients Using the Onyx Genome Engineering Platform - WWNY - October 5th, 2021
- Kingdom Supercultures raises $25m to expand Non GMO suite of microbes to unlock new flavors, textures, and functionalities in food & beverage -... - October 5th, 2021
- Fact check: Genetically engineering your salad with the COVID-19 vaccines? We're not there yet. - USA TODAY - October 5th, 2021
- Making the Transition from an Academic to a Biobusiness Entrepreneur - Genetic Engineering & Biotechnology News - October 5th, 2021
- Is The New York Times Finally 'Learning To Love GMOS'? - American Council on Science and Health - October 5th, 2021